Clinical Trials Logo

Clinical Trial Summary

Trial Title: Prospective, multicenter, single-arm target value clinical trial to evaluate the safety and efficacy of a transcatheter aortic valve system in the treatment of patients with severe aortic stenosis Test device: Transcatheter aortic valve system. Pilot Phase: Clinical Validation of Class III Medical Devices. Study design: prospective, multicenter, single-group target value. Sample size: 120 cases. Intended Use: The Transcatheter Aortic Valve System is indicated for patients with a diagnosis of severe aortic stenosis by the Comprehensive Heart Team. Objective: This clinical trial is a prospective, multicenter, single-arm study to evaluate the safety and efficacy of the transcatheter aortic valve system in the treatment of patients with severe aortic stenosis. Primary endpoint: 12-month postoperative all-cause mortality All-cause deaths include cardiac death and non-cardiac death. Secondary Endpoints: 1. Device success rate 2. Procedural success rate 3. Delivery system performance 4. Retrieval system performance (e.g. using a recycling system) 5. Exchange system performance 6. Valvular function at Immediately postoperative, 7 days/at discharge, 30 days, 6 months, 12 months, 2-5 years follow-up: valve stenosis, regurgitation, valve function (e.g., opening area, pressure gradient), paravalvular leakage 7. Improvement in quality of life at 30 days, 6 months, 12 months postoperatively 8. Improvement in cardiac function at 7 days/at discharge, 30 days, 6 months, 12 months, 2-5 years postoperatively Experimental design: This trial is a prospective, multicenter, single-group clinical study with a target value to evaluate the Transcatheter Aortic Valve system Safety and efficacy in the treatment of patients with severe aortic stenosis with 12 months of All-cause mortality after transcatheter aortic valve implantation. The mortality rate was the primary study endpoint, and after statistical assumptions and sample size calculations, 120 patients were planned to be enrolled. Patients were clinically followed immediately after valve implantation, 7 days postoperatively/at discharge, 30 days, 6 months, 12 months, and 2-5 years postoperatively. In this trial, all relevant clinical data were collected, sorted out and statistically analyzed by an independent data management and statistics center and a clinical monitoring institution. All enrolled subjects underwent outpatient follow-up at 30 days, 6 months, and 12 months after surgery, and performed relevant imaging examinations (ultrasound, etc.) and laboratory tests and safety evaluations, and continuous follow-up and cardiac ultrasound examinations were performed annually at 2-5 years to observe the occurrence of adverse events to evaluate the long-term safety of the transcatheter aortic valve system. The safety and efficacy of the transcatheter aortic valve system were evaluated with the subject's 12-month postoperative all-cause mortality as the primary endpoint, and the immediate postoperative device success rate, procedural success, retrieval system performance, valve function, cardiac function improvement, quality of life improvement, all-cause mortality in different follow-up periods, major adverse cardiovascular and cerebrovascular events, myocardial infarction, stroke, hemorrhage, acute kidney injury, permanent pacemaker implantation, serious vascular complications, and other TAVR-related complications were taken as the secondary endpoints to assist in evaluating the safety and efficacy of the test product, and to provide a basis for the final official listing and domestic marketing.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06136429
Study type Interventional
Source Chinese Academy of Medical Sciences, Fuwai Hospital
Contact TAO chunli
Phone 13701152794
Email taochunli@silaragroup.com
Status Recruiting
Phase N/A
Start date October 18, 2023
Completion date December 30, 2029

See also
  Status Clinical Trial Phase
Completed NCT01238497 - SOURCE XT REGISTRY
Recruiting NCT04029844 - Colibri Transcatheter Aortic Heart Valve System Study N/A
Recruiting NCT03280433 - Influence of EPICardial Adipose Tissue in HEART Diseases: EPICHEART Study N/A
Completed NCT05492383 - SAvvyWireâ„¢ EFficacy and SafEty in Transcatheter Aortic Valve Implantation Procedures (SAFE-TAVI) N/A
Active, not recruiting NCT03752866 - The CONFIDENCE Registry N/A
Completed NCT01651780 - Open-label, Randomized Trial in Patients Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH Phase 3
Recruiting NCT06173115 - Comparison of a Single Versus Double Perclose Technique for TAVR N/A
Not yet recruiting NCT06015997 - Prevalence of ATTR Cardiac Amyloidosis in Patients Undergoing TAVR
Recruiting NCT03291925 - Primary Non-invasive Cardiac Computed Tomography Versus Routine Invasive Angiography Prior to TAVI N/A
Terminated NCT03004599 - Safety and Efficacy of SYM-SV/DS-002 in Patients With Severe Aortic Stenosis N/A
Recruiting NCT04076150 - Safety and Performance Study of the Optimum Transcatheter Aortic Valve N/A
Completed NCT01074658 - CoreValve Advance International Post Market Study N/A
Completed NCT02575768 - Myocardial Flow Reserve in Severe AS Without Obstructive Coronary Artery Disease N/A
Completed NCT01994330 - Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement Surgery Phase 4
Completed NCT04286893 - Improved HRV, Inflammation Markers and Endothelial Function After TAVI
Not yet recruiting NCT06177392 - VARC-TAVI VALVE IMPLANTATION) N/A
Active, not recruiting NCT04206228 - Intravenous Iron Supplement for Iron Deficiency in Patients With Severe Aortic Stenosis Phase 2
Not yet recruiting NCT03788590 - Evaluate the Transcatheter Artificial Aortic Valve and Transcatheter Artificial Heart Values Delivery System N/A
Completed NCT01531374 - Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement N/A
Recruiting NCT05493657 - Aspirin vs Clopidogrel After TAVR N/A